Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry M Karnitz

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Cancer Research|November 23, 2021
Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian CarcinomaArun Kanakkanthara, Xiaonan Hou, Thomas L Ekstrom, et al.
Cell Metabolism|September 4, 2018
Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle PathwayKiran Kurmi, Sadae Hitosugi, Jia Yu, et al.
Blood|March 24, 2005
Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabineRuben A Mesa, David Loegering, Heather L Powell, et al.
Leukemia Research|September 29, 2017
Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemiaJonathan A Webster, Raoul Tibes, Larry Morris, et al.
Science Translational Medicine|January 14, 2026
Dual FAK and EPHA2 targeting by brigatinib tackles PARP inhibitor adaptive survival response in high-grade serous ovarian cancerJulie R Duffield, Xiaonan Hou, Benjamin W Wilson, et al.
Molecular Pharmacology|August 30, 2005
Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survivalLarry M Karnitz, Karen S Flatten, Jill M Wagner, et al.
Cancer Research|October 18, 2019
BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting AgentsArun Kanakkanthara, Kiran Kurmi, Thomas L Ekstrom, et al.
Cancer Research|January 8, 2021
CDK2-Mediated Upregulation of TNFα as a Mechanism of Selective Cytotoxicity in Acute LeukemiaHusheng Ding, Nicole D Vincelette, Cordelia D McGehee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2016
A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic LeukemiaKeith W Pratz, Michelle A Rudek, Ivana Gojo, et al.
Haematologica|July 28, 2011
Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemiaScott H Kaufmann, Judith E Karp, Mark R Litzow, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Cancer Research|November 23, 2021
Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian CarcinomaArun Kanakkanthara, Xiaonan Hou, Thomas L Ekstrom, et al.
Cell Metabolism|September 4, 2018
Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle PathwayKiran Kurmi, Sadae Hitosugi, Jia Yu, et al.
Blood|March 24, 2005
Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabineRuben A Mesa, David Loegering, Heather L Powell, et al.
Leukemia Research|September 29, 2017
Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemiaJonathan A Webster, Raoul Tibes, Larry Morris, et al.
Science Translational Medicine|January 14, 2026
Dual FAK and EPHA2 targeting by brigatinib tackles PARP inhibitor adaptive survival response in high-grade serous ovarian cancerJulie R Duffield, Xiaonan Hou, Benjamin W Wilson, et al.
Molecular Pharmacology|August 30, 2005
Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survivalLarry M Karnitz, Karen S Flatten, Jill M Wagner, et al.
Cancer Research|October 18, 2019
BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting AgentsArun Kanakkanthara, Kiran Kurmi, Thomas L Ekstrom, et al.
Cancer Research|January 8, 2021
CDK2-Mediated Upregulation of TNFα as a Mechanism of Selective Cytotoxicity in Acute LeukemiaHusheng Ding, Nicole D Vincelette, Cordelia D McGehee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2016
A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic LeukemiaKeith W Pratz, Michelle A Rudek, Ivana Gojo, et al.
Haematologica|July 28, 2011
Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemiaScott H Kaufmann, Judith E Karp, Mark R Litzow, et al.
Pageof 6